Efficacy and Safety of Sintilimab Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline Resectable HCC

NCT06904014 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

HCC

Interventions

PROCEDURE: HAIC
DRUG: Sintilimab
DRUG: Lenvatinib
PROCEDURE: surgery

Sponsor

Lei ZHAO